Cardio drug Bayer and J & J fails in attempts to expand indications for use
The company’s Bayer and Johnson & Johnson campaigns to expand the market for Xarelto cardioplasm failed after a potentially new subgroup of patients showed no statistically significant benefits, Reuters reported. Recall that the anticoagulant Xarelto – one of the most successful drugs J & J, which brought this company about $ 2 billion in 2017,…